Investor relations.

Let’s change the way severe diseases are detected and monitored

Detection of a disease at an early stage is essential to ensure effective and good recovery. This is true for many different types of diseases from cancers to infectious diseases.

Due to the need for better and earlier diagnosis and the impact of AI, the diagnostics market is moving toward multi-omics approaches, where several biomarkers complement each other. This enables earlier and more accurate detection of diseases. Aqsens Health’s AQ Biosensor is at the forefront of this transition.

AQ Biosensors provide a robust platform for both precise disease detection and systematic biomarker discovery. By facilitating early-stage diagnostics from non-invasive samples like urine and saliva, this cost-effective technology has the potential to challenge and enhance existing gold standard methods in the field.

We strive to improve the early detection of several high-impact diseases to build a healthier world.

We want to improve health and well-being for everyone, worldwide. We believe that our biosensor technology will become one of the leading non-invasive screening and testing methods while paving the way in discovering new disease biomarkers from biological samples.
We want to work with talented people and research organizations, who share our goals and values. Let’s change the world for the better, together.
Aqsens Health’s AQ Biosensors delivers an exceptional amount of new information on specific disease targets quickly and at a low cost. It helps in the discovery of new disease biomarkers and enables cost-efficient screening of different diseases from cancers to infectious diseases.
We’re well connected globally and have ongoing research studies and validation projects in Finland, China, Ghana and the US. Our business strategy aims to benefit from strategic partnerships in both the developing economies and the developed world.
The size of the in-vitro diagnostic market was over 80 billion dollars in 2023, and the market is expected to grow at a CAGR of 6.6%. Non-invasive diagnostics, such as urine and saliva based testing, are gaining in market share and becoming a high growth segment with clear competitive advantages over blood based testing. Non-invasive sampling offers new possibilities in finding new biomarkers and is also a more cost-efficient way to detect health disorders at large scale.
The in-vitro diagnostic market in the European Union is projected to reach 18 billion dollars by 2027. The largest segments within the IVD market are infectious disease and cancer diagnostics.
The in-vitro diagnostics market in China is rapidly growing and is expected to reach 17 billion dollars in 2023. The large aging population needs better and more cost-efficient diagnostics to manage the growing prevalence of chronic and infectious diseases.
Aqsens Health's AQ Biosensor enables the systematic discovery process of new disease biomarkers from urine and saliva. We operate in a high growth area in which global diagnostic companies are entering using traditional analytical measurement methods. The technology is well protected with a patent portfolio and it has the potential to revolutionize disease diagnostics in the coming years.
Aqsens' team consists of science-driven professionals in the field of biosensors and disease detection. We work closely together with dedicated clinical and scientific institutes and advisors, who are world-class medical professionals within their own fields.
As a company we are looking for 5 - 10 x ROI for the coming 3 to 5 years.